Clene Inc. to Showcase Corporate Updates at Emerging Growth Conference

Clene Inc. (NASDAQ: CLNN), a clinical-stage biopharmaceutical company at the forefront of developing treatments for neurodegenerative diseases such as ALS and MS, is set to present a corporate update at the Emerging Growth Conference on August 20, 2025. The presentation, scheduled for 2:20 p.m. ET, will be followed by a Q&A session, offering investors and the public a deeper insight into the company's progress and future directions. This event is particularly significant for stakeholders interested in the advancements of neurodegenerative disease treatments, as Clene's innovative approach targets mitochondrial health and neuronal function.

The virtual session will be accessible via a live webcast through the Events section of Clene’s website or through the conference registration link. Additionally, replays will be made available on the conference portal and YouTube channel, ensuring broader access to this valuable information. Clene's participation in the Emerging Growth Conference underscores the company's commitment to transparency and engagement with the investment community and the public at large.

Clene's focus on neurodegenerative diseases addresses a critical unmet medical need, with its investigational therapy, CNM-Au8®, representing a potential breakthrough in improving central nervous system cells' survival and function. The company's research and development efforts, particularly in targeting mitochondrial function and the NAD pathway while reducing oxidative stress, could pave the way for novel treatments for diseases like amyotrophic lateral sclerosis, Parkinson’s disease, and multiple sclerosis. For more details on Clene's innovative work, visit their latest press release.

This presentation is a key opportunity for investors and the medical community to gain insights into Clene's strategic direction and the potential impact of its therapies on the treatment of neurodegenerative diseases. The company's presence at the Emerging Growth Conference highlights its role as a leader in biopharmaceutical innovation, with the potential to significantly improve patient outcomes in a challenging area of medicine.